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Abstract
Background: Accumulating evidence supports that tumor growth and cancer relapse are driven by cancer stem cells. Our
previous work has demonstrated the existence of CD90
+ liver cancer stem cells (CSCs) in hepatocellular carcinoma (HCC).
Nevertheless, the characteristics of these cells are still poorly understood. In this study, we employed a more sensitive RNA-
sequencing (RNA-Seq) to compare the gene expression profiling of CD90
+ cells sorted from tumor (CD90
+CSCs) with parallel
non-tumorous liver tissues (CD90
+NTSCs) and elucidate the roles of putative target genes in hepatocarcinogenesis.
Methodology/Principal Findings: CD90
+ cells were sorted respectively from tumor and adjacent non-tumorous human liver
tissues using fluorescence-activated cell sorting. The amplified RNAs of CD90
+ cells from 3 HCC patients were subjected to
RNA-Seq analysis. A differential gene expression profile was established between CD90
+CSCs and CD90
+NTSCs, and
validated by quantitative real-time PCR (qRT-PCR) on the same set of amplified RNAs, and further confirmed in an
independent cohort of 12 HCC patients. Five hundred genes were differentially expressed (119 up-regulated and 381 down-
regulated genes) between CD90
+CSCs and CD90
+NTSCs. Gene ontology analysis indicated that the over-expressed genes in
CD90
+CSCs were associated with inflammation, drug resistance and lipid metabolism. Among the differentially expressed
genes, glypican-3 (GPC3), a member of glypican family, was markedly elevated in CD90
+CSCs compared to CD90
+NTSCs.
Immunohistochemistry demonstrated that GPC3 was highly expressed in forty-two human liver tumor tissues but absent in
adjacent non-tumorous liver tissues. Flow cytometry indicated that GPC3 was highly expressed in liver CD90
+CSCs and
mature cancer cells in liver cancer cell lines and human liver tumor tissues. Furthermore, GPC3 expression was positively
correlated with the number of CD90
+CSCs in liver tumor tissues.
Conclusions/Significance: The identified genes, such as GPC3 that are distinctly expressed in liver CD90
+CSCs, may be
promising gene candidates for HCC therapy without inducing damages to normal liver stem cells.
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Introduction
Hepatocellular carcinoma (HCC) is the fifth most common
cancer in the world with a high mortality rate [1]. Most HCC
patients present at an advanced stage, which is refractory to
chemotherapy and radiotherapy [2,3]. Moreover, the recurrence
rate of this disease is very high after curative treatment [4].
Understanding the mechanism of carcinogenesis is pivotal for the
management of HCC [5].
Lines of evidence have revealed the existence and importance of
cancer stem cells (CSCs) in carcinogenesis in the past decades.
CSCs are considered to be the root of cancers, and are responsible
for tumor growth and differentiation of heterogeneous cell
populations within tumors [6]. Additionally, they have been
demonstrated to be chemoresistant [7] and radioresistant [8]. In
our previous study, using the surface marker CD90 (Thy-1,
expressed by hepatic stem/progenitor cells), liver CSCs were
identified in HCC cell lines, tumor specimens and peripheral
blood samples of HCC patients and these CD90
+CSCs displayed
tumorigenic capacity [9].
Since the capacities of tumorigenicity, differentiation, self-
renewal and chemoresistance of liver CD90
+CSCs are governed
by their distinctive genetic makeup and an array of gene
expression changes in biological processes, elucidation of their
molecular profile is important in understanding the characteristics
of these cells. Nevertheless, comprehensive gene expression
profiling of liver CSCs remains to be determined.
In the past decades, cDNA microarray has been extensively used
to identify differential gene expression profiles in many cancers for
screening, prognosis and tumor classifications [10–13]. However,
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sensitivity, low dynamic ranges [14], and hybridization artifacts
[15]. In fact, the majority of genes in biological processes, such as
those encoding transcription factors and signal transducers, usually
express at low levels [16]. Hence, cDNA microarray may not be an
ideal tool to delineate molecular pathways. In this study, we used
next-generation RNA sequencing (RNA-Seq), taking advantage of
its superior sensitivity and capability of detecting splice variants, to
sequencethewholetranscriptomesofliverCD90
+CSCsandCD90
+
non-tumorous stem cells (NTSCs) from three HCC patients. The
differential expression of genes was examined between these two
groups ofCD90
+cells and the results werevalidated byquantitative
reverse transcriptase polymerase chain reaction (qRT-PCR).
Concordant results were indicated between the platforms of RNA-
Seq and qRT-PCR, and a majority of transcripts were detected at
lowexpressionlevelsbyRNA-Seq.Besides,morestructuralisoforms
were found in liver CD90
+CSCs than CD90
+NTSCs. Further,
Gene Ontology (GO) analysis indicated that the up-regulated genes
were associated with drug metabolism, lipid metabolism and
inflammation which may account for drug resistance, cell prolifer-
ation, and progression of the tumor. Among the up-regulated genes
identified, Glypican-3 (GPC3), a member of glypican family of
heparan sulfate proteoglycans, was over-expressed in CD90
+CSCs.
By immunohistochemical staining, GPC3 was detected in the
majorityoflivertumortissues,butabsentinadjacentnon-tumorous
tissues. Interestingly, the GPC3 expression level was positively
correlated to the number of CD90
+CSCs in liver tumor tissues.
Further investigation by flow cytometry indicated that GPC3 was
remarkably expressed in CD90
+CSCs in human liver tumor
specimens. Based on our current findings, regardless of ambiguous
rolesofGPC3onlivercancerstemcells,GPC3couldbeapromising
target gene for HCC immunotherapy owing to its specificity on the
liver cancer stem cells, and its absence in normal liver stem cells.
Materials and Methods
Patients and sample collection
All patients signed a written informed consent, and the data and
samples were analyzed anonymously. The present study was
approved by the Institutional Review Board of The University of
Hong Kong. A total of 15 patients were recruited for RNA-
Sequencing and validation in this study (Table 1). The mean age
of these patients was 57. There were 14 men and 1 woman.
Thirteen of these patients were positive for serum hepatitis B
surface antigen and 1 for hepatitis C antibody. Eighty-seven
percent of these patients presented at tumor-node-metastasis
(TNM) stage III or IV with a mean tumor size of 9.3 cm. The
three HCC patients whose specimens were studied by RNA-Seq
were male, aged from 55 to 61. All were hepatitis B virus carriers.
Two had TNM stage III cancer and one had TNM stage II
cancer. Pathological diagnosis was made according to the histology
of tumor specimens examined by experienced pathologists.
Tumor and parallel non-tumorous liver tissues were harvested at
the time of operation. The cell isolation procedure from liver tissues
was performed as previously described with somemodifications [9].
In brief, after digestion with 100 units/ml type IV collagenase
(Sigma-Aldrich,StLouis,MO,USA)for30 minutesat37uC,tissues
were minced and cell suspension was passed through a 100-mm
nylonmeshtoremovetissuedebris.Redbloodcells(RBC)werethen
lysed by RBC lysis buffer and the cell suspension was washed again,
finally passed through a 40-mm nylon mesh. Cells were resuspended
with buffer and HetaSep (Stem Cell Technology, Vancouver, BC,
Canada) was then added into the cell suspension for removal of
remaining debris. After dead cell removal, the cells were eventually
resuspended in staining buffer (2% BSA, 2 mM EDTA in PBS),
counted and subjected to flow cytometry analysis and cell sorting.
Cellswerealsosortedontoglassslide,counterstainedwithDAPIand
examined under fluorescence microscope.
Cell lines
PLC and MHCC97L cell lines [9] were maintained as
monolayer culture in high glucose DMEM with 10% fetal bovine
serum and 1% penicillin/streptomycin (Life Technologies, Carls-
bad, CA, USA) at 37uC in a humidified atmosphere of 5% CO2 in
air.
Fluorescence-activated cell sorting (FACS) for CD90
+ cells
The isolated cells from tumor and non-tumor tissues were
labeled with PE-conjugated anti-human CD90 and APC-conju-
gated anti-human CD45 antibodies (BD Pharmingen, San Diego,
CA, USA). Subsequently, CD45
2CD90
+ cells were isolated using
a BD FACSAria II Cell Sorter (Becton Dickinson Immunocyto-
metry Systems, San Jose, CA, USA). An aliquot of CD90
+ cells
were checked for purity. The isolated cells were further treated
with RNA
TMsafer RNA stabilization reagent (SABiosciences,
Frederick, MA, USA) and the cell pellets were stored at 280uC
for subsequent RNA isolation.
Flow Cytometry analysis of HCC cell lines and human
liver tumor tissues for GPC3 and CD90
Initially viable PLC and MHCC97L cells and viable cells from
human liver tumor tissues after digestion were sorted using Sytox
Blue (Invitrogen) according to the manufacturer’s instruction, then
the cells were fixed and permeabilized with the fixation/
permeabilization kit (BD Biosciences, San Diego, CA, USA).
After washing, the cells were stained with a PE-conjugated anti-
CD90 (BD Pharmingen, San Diego, CA, USA) and an anti-GPC3
antibody (Santa Cruz Biotechnology, Santa Cruz, CA, USA)
labeled with ZenonH Alexa FluorH 488 mouse IgG1 Labeling Kit
Table 1. Clinicopathological features of HCC patients used
for RNA-Seq analysis and the prospective validation of RNA-
Seq analysis by qRT-PCR.
Clinicopathological details of
patients (N=15) Frequency
Mean Age (Range) 57(41–83)
Sex
Male 14
Female 1
HBV 13
HCV 1
TNM stage
I 0
II 2
III 8
IV 5
Mean Tumor Size (Range) 9.3 cm (2–18)
Mean Serum AFP (Range) 17,244 ng/ml (3–211,427 )
The three HCC patients whose specimens were studied by RNA-Seq were male,
aged from 55–61. All were HBV carriers. Two had tumor TNM stage III and one
had tumor TNM stage II.
doi:10.1371/journal.pone.0037159.t001
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tion and washing, the stained cells were detected and counted by a
BD FACSAria II (Becton Dickinson Immunocytometry Systems,
San Jose, CA). Appropriate isotypes were used as controls.
RNA isolation and RNA amplification
Total cellular RNAs were extracted from the isolated
CD45
2CD90
+ cell pellet using an RNAqueous-Micro RNA
isolation kit (Ambion, Austin, TX, USA). The RNA samples
(,50 ng) were then amplified with a MessageAmp II aRNA
Amplification kit (Ambion) according to the manufacturer’s
instruction. In brief, a double stranded cDNA was synthesized
by reverse transcription from RNA with a T7 promotor primer.
After purification, the double-stranded cDNA acted as a template
for in vitro transcription to generate multiple copies of amplified
RNA (aRNA). Following RNA amplification, the aRNA was
subjected to a second round of amplification with the same
methodology as the first amplification except using a different
primer provided by the manufacturer. A control Hela RNA was
also run in parallel with the RNA samples during the amplification
procedure. After completion of amplification, the concentration of
aRNA was measured using Nanodrop ND-1000 and the quality of
the aRNA was analyzed by the Bioanalyzer 2100 (Agilent
Technologies, Santa Clara, CA, USA).
RNA library preparation and sequencing
RNA-library preparation was performed according to the
manufacturer’s recommendations. In brief, the poly-A containing
aRNAs were purified, followed by fragmentation of RNA into
small pieces. The cleaved RNA fragments were synthesized into
single-strand cDNA using superscript II reverse transcriptase
(Invitrogen) and random hexa-primers (IDT, Coralville, Iowa,
USA), followed by second strand synthesis with DNA polymerase I
(Invitrogen) and E. coli RNase H (Invitrogen). After second strand
synthesis, with end repair and A-tailing, the synthesized double-
stranded cDNA fragments were subjected to purification, then
ligated to Illumina adapters using Quick ligation TM kit (NEB)
and DNA ligase. The resultant cDNA adapter-modified cDNA
libraries were fractionated on agarose gel, 200-bp fragments were
excised and amplified by 15 cycles of polymerase chain reaction.
After purification, the quality of cDNA libraries was checked by
Bioanalyzer 2100 (Agilent). The concentration of cDNA libraries
was measured and diluted to 10 nM in Tris-HCl buffer prior to
cluster generation. Cluster formation, primer hybridization and
sequencing reactions were performed sequentially according to the
manufacturer’s recommended protocol. In the present study, we
used pair-end sequencing by Illumina Genome Analyzer II
(Illumina, San Diego, CA, USA) with 76 cycles. One lane of flow
cell was used for each sample. Raw short sequence fragments were
accepted if they passed the quality filtering parameters used in the
Illumina GA Pipeline GERALD stage.
Read mapping and gene expression
High-quality reads were aligned to the human reference genome
(NCBI Build 36.1) using NextGENeH software (Softgenetics, State
College, PA, USA). The matched reads were aligned to Human
Refseq mRNA (NCBI). Reads shorter than 20 bps and those with
the quality score less than 14 were excluded. The sequences aligned
with individual transcript were counted digitally. The expression
levels for each gene were normalized to reads per kilobase of exon
model per million mapped reads (RPKM) to facilitate the
comparison of transcripts among samples. Tophat software was
used to identify splice variants of each sample [17].
RNA-Seq data mining and defining mis-regulated genes
across the patients
A large database containing all gene transcripts identified by
RNA-Seq for the samples of CD90
+ cells from paired tumor and
non-tumorous tissues of 3 patients were assembled. A mean log2
fold change [RPKM of CD90
+CSCs/RPKM of CD90
+NTSCs]
of each gene was calculated across all 3 patients. The false
discovery rate (FDR, i.e. a probability of wrongly accepting a
difference between these two tested CD90
+ cell groups) of each
gene was determined according to Storey’s method [18]. The
genes were regarded as differentially expressed when their FDRs
were less than 0.05. Further, genes were classified as up-regulated
when their mean log2 fold change ratio was larger than 1 or down-
regulated when their log2 fold change ratio was less than 21.
Fluidigm microfluidic chips for qRT-PCR
To validate the reliability of RNA-Seq data, initially we
performed qRT-PCR using the same amplified RNA materials
as an internal validation, followed by original, non-amplified RNA
from an independent HCC patient cohort as a prospective
validation. BioMarkH Real-Time PCR System 48.48 Dynamic
Array (Fluidigm, South San Francisco, CA, USA) was used to
perform the qRT-PCR according to the manufacturer’s protocols.
EvaGreen and TaqMan assays were done according to the
manufacturer’s protocols. The primers of selected genes were
designed using Primer 3 software (Table S1). TaqMan Universal
Master Mix, TaqMan PreAmp Master Mix and probes were
purchased from Applied Biosystems (ABI, Foster City, CA, USA).
Samples were run at least in duplicate. The gene expression level
was normalized by subtracting the cycle threshold (Ct) of an
abundantly-expressed control gene from the Ct for each selected
gene of interest. Relative gene expression values expressed as fold
change were subsequently determined using the 2
2DDCT method.
GAPDH was used as the reference control gene and the
CD90
+NTSCs were taken as the reference samples. Data were
analyzed using the BioMark Real-Time PCR Analysis Software
version 2 (Fluidigm).
The quantification of gene expression of GPC3 was performed
by Fluidigm Digital Array. The assay was performed according to
the manufacturer’s protocol and the data were analyzed by the use
of BioMark Digital PCR Analysis software (Fluidigm).
Quantification of CD90
+ cells in human liver tumor
samples by flow cytometry
Tumor and parallel non-tumorous liver tissues were obtained
from another forty-two HCC patients at the time of hepatectomy.
A portion of each resected tissues was fixed in 10% formalin and
embedded in paraffin. The remaining portion underwent the same
procedures of FACS for CD90
+ cells as described above and the
number of CD90
+ cells were analyzed and quantified by BD
FACSCalibur flow cytometer (Becton Dickinson Immunocytome-
try Systems).
Immunohistochemical staining of GPC3 in human liver
tumor samples
The embedded tissues were cut into 5-mm thick sections for
immunohistochemical staining of GPC3. The sections were
initially deparaffinized in xylene and rehydrated through ethanol
to water. The sections were then treated with 3% hydrogen
peroxide in methanol for 20 minutes to abolish endogenous
peroxidase activity. For antigen retrieval, sections were heated in
10 mM citrate buffer (pH 6.0) with pressure cooker for 5 minutes
at 120uC. The sections were subsequently covered with a 1:1000
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Cruz Biotechnology, California, USA) for 1 hour at room
temperature. After washing with TBS-Tween 20, the sections
were incubated with envision Polymer-horseradish peroxidase
(DakoCytomation, Carpenteria, CA, USA), which was used as a
secondary antibody for 30 minutes at room temperature. The
color signal for GPC3 of each section was developed by the
addition of 3, 3 diaminobenzidene tetrahydrochloride (DakoCy-
tomation), followed by 2 minute incubation. Finally the sections
were washed with distilled water and counterstained for nuclei
with 10% hematoxylin and dehydrated. The analysis of immuno-
histochemistry was performed by independent researchers. The
GPC3 expression was assessed using an ‘‘H score’’ system, which
was obtained by the following formula:
3X percentage of strong staining+2X percentage of moderate
staining+percentage of weak staining [19].
Small Interfering RNA (siRNA) transfection in vitro
A specific GPC3-siRNA and a scrambled siRNA control (SSC)
were purchased from Ambion (Austin, TX). CD90
+GPC3
+ cells
were sorted from PLC cells for subsequent functional assays, as
PLC cells express relatively high CD90 and GPC3. GPC3
knockdown was achieved by transfecting siRNA oligo into the
sorted cells using the reverse transfection with Lipofectamine
RNAiMAX reagent (Invitrogen) according to the manufacturer’s
instructions at a final concentration of 20 nM siRNA. These
transfected cells are henceforth annotated as PLC
CD90
+GPC3
+(GPC32). In parallel, PLC CD90
+GPC3
+cells were
transfected with the scrambled siRNA control at a final
concentration of 20 nM, which are henceforth annotated as
PLC CD90
+GPC3
+ (ssc).
Cell proliferation Assay
PLC CD90
+GPC3
+(GPC32) and CD90
+GPC3
+ (ssc) cells were
seeded onto a 96-well plate at a density of 4,000 cell/well in
DMEM/10% FBS. At the indicated time points, 10 ul of WST-1
reagent (Roche Applied Science, Madison, WI, USA) was added
into each well containing 100 ul medium. The plate was incubated
for 2 hours, followed with 1 minute shaking. Cell growth was
assessed by measuring absorbance at 450 nm using a microplate
reader (Thermo Fisher Scientific, Waltham, MA, USA ) on day 1,
2, 3 and 4. Each sample was run in triplicate and expressed as
mean6SD. At least two independent experiments were per-
formed.
Stem cell colony formation assay
Clonogenic capacity of cancer stem cells was assessed by stem
cell colony formation assay. The CD90
+GPC3
+ cells were isolated
from PLC cells, followed by transfection with GPC3 siRNA and
scrambled siRNA control, respectively. The CD90
+GPC3
+(GPC32)
and CD90
+GPC3
+ (ssc) were seeded into semisolid agar media
using StemTAG TM 96-well stem cell colony formation assay kit
(Cell Biolabs, Inc. San Diego, CA, USA) according to the
manufacturer’s instruction. In brief, 50 ul of Base Agar Matrix
Layer was dispensed into each well of a 96-well plate and solidified
at 4uC. Seventy-five ul of cell suspension/agar matrix suspension
containing 5,000 cells was dispensed into each well. After
solidifying, 50 ul of culture medium with growth factors was
added into each well and the cells were incubated for 8 day in the
humidified incubator at 37uC with 5% CO2. The colony
formation ability was examined under a microscope, and the
results were then determined by quantifying alkaline phosphatase
activity after cell lysis.
Statistical analysis
The continuous variables were expressed as mean 6 S.D or
median. Comparisons of the fold change of genes and splice
variants between two groups were performed by Student’s t-test.
Correlation between measured genes between RNA-Seq and
qRT-PCR was measured by Spearman rank correlation coeffi-
cient. All analyses were performed with the GraphPad Prism 5
software (GraphPad Software, La Jolla, CA, USA). A P value less
than 0.05 was considered statistically significant.
Results
Isolation of CD90
+ cells from tumor and non-tumor
specimens
Both anti-human CD90 and anti-human CD45 antibodies were
used in the isolation procedures. As CD90 was also expressed by
some lymphocytes, a combination of CD45
2CD90
+ was used to
define nonlymphatic CD90
+ cells in the patient liver tissues (Figure
S1). The BD cell sorter sorted CD90
+ cells with an average purity
of 86.6%. A median number of 3.4610
4 CD90
+CSCs from tumor
tissues and 8.9610
3 cells of CD90
+NTSCs from non-tumorous
tissues were obtained. The number of CD90
+CSCs was signifi-
cantly higher than that of CD90
+NTSCs (P=0.0008). The sorted
CD90
+cells were further confirmed by immunofluorescence
staining before RNA extraction.
RNA extraction and amplification
The yield of RNA from the sorted CD90
+ cells ranged from
12 ng to 200 ng (from 10
3 to 10
4 cells). Owing to the insufficient
amount of RNA for RNA-Seq, two rounds of RNA amplification
were performed according to the manufacturer’s procedures. After
amplification, an average of 114 mg of amplified RNA (aRNA) was
obtained. The sizes were in the range of 200–2000 nucleotides,
with the majority being around 500, which is in concordance with
the specifications of the sizes of aRNA stated by the manufacturer,
indicating that the aRNA samples were in good quality.
Regarding the bias of RNA amplification in the RNA-Seq
technology, no comparison data has ever been found in the
literature yet. Nevertheless, it has been demonstrated that one or
two rounds of RNA amplification generated reproducible micro-
array data without significant loss of gene detection [20].
Additionally, a study showed that 75% more genes were detected
by mRNA sequencing compared to microarray after cDNA
amplification on a single cell [21]. Hence, we believed that the
produced aRNAs could also be used for RNA-Seq.
Sequencing-by-synthesis of amplified RNA isolated from
CD90
+CSCs and CD90
+NTSCs on Illumina Genome
Analyzer II
The amplified RNAs after construction of a cDNA library were
subjected to RNA-Seq on Illumina Genome Analyzer II (pair-end
sequencing). On completion, 14.9 million to 20.5 million 75-bp
long sequence reads per sample were generated, and they
corresponded to an average of 1.30 Gb raw sequence data.
Alignment to mRNA Reference Sequence (NCBI) was 39.467%
with a greater portion of reads aligned to the reference human
genome (70.368%) (Table 2), suggesting that the unaligned
sequences to RefSeq was probably due to incomplete annotation
of mRNA isoforms in Homo sapiens [22,23]. Other causes might
be attributed to their origins outside the reference human genome
or low sequence quality [24]. Nevertheless, the average number of
transcripts detected in CD90
+CSCs and CD90
+NTSCs were
31,40762,202, and 31,4446479, respectively, which correspond-
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significant difference in the number of transcripts was found
between the two types of CD90
+ cells, the gene comparison was
considered to be valid (P=0.7).
Alternative precursor messenger RNA (pre-mRNA) splicing
plays important roles in the generation of functional diversity of
the genome. Accumulating evidence has revealed that aberrant
splicing contributes to neoplasia, cancer progression and metas-
tasis [25–27]. Splicing events including alternative 39 or 59 splice
site, alternative first exon, alternative last exon, intron retention,
and exon skipping were compared between CD90
+CSCs and
CD90
+NTSCs (Table 3). The average numbers of alternative
splicing of CD90
+CSCs were found to be 383, whereas those of
CD90
+NTSCs were 245 (P,0.05). More structural variants were
found in CD90
+CSCs as compared to CD90
+NTSCs, indicating
that more regulatory and functional diversity of transcriptomes
occurred in liver CSCs.
The distribution of transcripts in CD90
+CSCs and
CD90
+NTSCs exhibited similar patterns (Figure 1). We observed
that 80% of transcripts had less than 10 RPKM in CD90
+CSCs or
CD90
+NTSCs, but only about 0.1% of the expressed transcripts
had more than 1000 RPKM. This implied that the majority of
transcripts were expressed at low levels and might not be easily
identified by the cDNA microarray. A similar transcript distribu-
tion pattern was found in the study of gene expression profiling in
glioblastoma using the next-generation sequencing technology
[28]. This again demonstrates high sensitivity of RNA-Seq in
detecting lowly expressed transcripts in cancer cells [29].
Analysis of gene expression profiles of CD90
+CSCs and
CD90
+NTSCs
Upon removal of duplicate genes after aligning transcripts to the
Human RNA Reference Sequence, the gene expression profiles of
24,609 genes were analyzed. Five hundred genes were differen-
tially expressed, among which 119 genes were up-regulated, and
381 were down-regulated.
In the previous and present studies, we used anti-human CD90
antibody to isolate CD90
+CSCs and CD90
+NTSCs from patient
tumor tissues because CD90 is a surface marker for hepatic stem
cells (oval cells) [30]. These two groups of cells exhibited similar
stem cell properties, as reflected from the genes involved in
pluripotency and differentiation (Table 4) expressing at similar
levels, suggesting their origin from the hepatic stem cells.
Housekeeping genes were expressed at comparable levels in
CD90
+CSCs and CD90
+NTSCs, indicating that the expression
changes of other genes could be reasonably compared between
these two groups (Table 4).
Representative features of differentially expressed genes in
CD90
+CSCs and CD90
+NTSCs were summarized (Table 5, up-
regulated and Table 6, down-regulated). The up-regulated genes
were associated with biological functions including drug transport
(ABCC5), lipid metabolism (APOE, APOC1), angiogenesis
(COL15A1, PLAU, PLVAP), cell proliferation (ESM-1, FGL1,
GPC3, IGFBP5), transport (AMBP), acute inflammatory response
(APOA2, ORM1), cytokine production (FABP4), cell cycle
(PLK2), signal transduction (RAP2A), and activation of MAPK/
ERK pathway (CXCR4). Down-regulated genes were involved in
several biological processes including organ development
(ADAMTS1, ALDH1A2), response to hypoxia (ANGPTL4,
EDN1, SOCS3, VEGFA), nucleotide binding (ATP2A3, RAN,
RPLP2), translation elongation activity (EEF1D), and chemotaxis
(IL8, CXCL1).
Validation of RNA-Seq data by qRT-PCR
To verify the RNA-Seq data, the original six amplified RNA
samples used for RNA-Seq were tested again by qRT-PCR on a
panel of 47 differential expressed genes. Selected genes included
28 up-regulated genes and 19 down-regulated genes. Log2 fold
change of genes of qRT-PCR was compared with that of RNA-
Seq. These two gene expression analysis platforms demonstrated
concordant results (Spearman Rank Correlation=0.88, P,0.001;
Figure 2). In addition, the slope of the regression line was 0.73,
suggesting that RNA-Seq had a similar dynamic range of detection
as that of qRT-PCR, and hence our RNA-Seq method could
reliably measure gene expression differences, particularly for those
lowly expressed genes in the CD90
+CSCs and CD90
+NTSCs.
Table 2. Alignment statistics for transcriptome reads of CD90
+ cells isolated from tumor and non-tumor tissues from 3 HCC
patients.
Patient A Patient B Patient C
CD90
+CSCs CD90
+NTSCs CD90
+CSCs CD90
+NTSCs CD90
+CSCs CD90
+NTSCs
Total Reads Processed 19.1 M (100%) 20.5 M (100%) 16.4 M (100%) 16.1 M (100%) 14.9 M (100%) 17 M (100%)
Reads matched to Ref RNA 7.7 M (40.3%) 10 M (48.7%) 5.3 M (32.3%) 5.02 M (31.1%) 5.5 M (37%) 8.0 M (47.2%)
Reads matched to Ref Genome 14.8 M (77.6%) 14.7 M (71.8%) 9.8 M (60%) 9.8 M (61%) 10.9 M (73.3) 13.3 M (78.1%)
Transcript matches (1000 s) 33.4 31.3 32.4 32.2 29.2 31.5
Average transcript coverage 186 286 166 156 186 246
Reads counts are expressed in million or a percentage of the total reads processed for each sample in parentheses.
doi:10.1371/journal.pone.0037159.t002
Table 3. Alternative splicing of CD90
+CSCs and CD90
+ NTSCs.
CD90
+CSCs CD90
+NTSCs
Alternative 39 splice site 127 77
Alternative 59 splice site 115 74
Alternative first exon 23 15
Alternative last exon 11 11
Mutually exclusive exon 1.7 0.3
Intron retention 44 23
Exon skipping 61 45
Total number of alternative
splicing events
383 245
Events are expressed as means. More alternative splicing events were observed
in CD90
+CSCs as compared with CD90
+NTSCs (P,0.05).
doi:10.1371/journal.pone.0037159.t003
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To eliminate potential bias as a result of pre-amplification and to
further validate the RNA-Seq results, qRT-PCR of 27 up-regulated
genes and 15 down-regulated genes was performed in 12 pairs of
RNA samples prepared from CD90
+CSCs and CD90
+NTSCs
derivedfromanindependentbatchoftumorandparallelnon-tumor
tissues, respectively. None of these samples underwent RNA
amplification nor assayed for RNA-Seq analysis. A gene expression
difference wasconsideredto bevalid ifthe trendofchangeofagene
measured by qRT-PCR agreed with that determined by the RNA-
Seq analysis. Twenty-two out of 27 (81.5%) selected up-regulated
genes were concordant with the trend estimated by RNA-Seq,
whereas 12 out of 15 (80.0%) selected down-regulated genes were
correlated with the down-regulated pattern estimated by RNA-Seq
(Figure 3). This high concordant result suggested that RNA
amplification did not introduce bias to the results of the gene
expression profiling under study.
We found that APOE, ESM-1, H19, ITIH1, PLVAP, PLK2,
and LAMB1 were highly expressed in CD90
+CSCs compared to
CD90
+NTSCs (P,0.01). The expression of GPC3 was unambig-
uously confined to CD90
+CSCs and not detected in most of the
CD90
+NTSCs (Figure 4A). The absence of GPC3 in
CD90
+NTSCs was further demonstrated by Fluidigm digital
array in human HCC tissues (P,0.05; Figure 4B).
Functional annotation of differentially expressed genes
by gene ontology analysis
To more systematically examine the enriched genes related to
the liver CSCs, we used the gene ontology (GO) enrichment
analysis to functionally annotate and predict the biological roles of
these differentially expressed genes. We performed the GOTM
((http://bioinfo.vanderbilt.edu/gotm/goanalysis_page_one.php)
and ProfComp (http://webclu.bio.wzw.tum.de/profcom/start.
php) analysis for clustering the genes with related biological
functions (Table 7). Up-regulated genes in liver CSCs were
associated with biological processes such as response to external
stimulus (CXCR4, APOE, LAMB1), response to chemical
stimulus (ABCC5, CRP, APOH, KNG1), inflammatory response
(CRP, TF, C4BPB), homeostasis (SERPIND1, APOE, HRG),
cholesterol transport and phospholipid efflux (APOE, APOC1,
APOA1). Besides, the 43 up-regulated genes, present in extracel-
lular regions and space, including COL4A1, PLVAP, IGFBP5,
GPC3, ITIH1 and ESM-1, were involved in remodeling of
extracellular matrix. Being a critical component of tumor
environment, extracellular matrix was important for the produc-
tion of secretory proteins which affected various biological
activities, such as metastasis. On the other hand, down-regulated
genes in CD90
+CSCs were those over-expressed in
CD90
+NTSCs. These over-expressed genes were related to
biological processes, such as translational elongation (RPL39,
EEF1B2, FAU), cell motion (IL-8, EDN1, CCL2, IL6), anti-
apoptosis (SOCS3, IL-6, HSPB1), negative regulation of cellular
process (TIMP1, BIRC3, VEGFA), angiogenesis (Jun, VEGFA,
ANGPTL4), and cell proliferation.
Figure 1. Bar chart showing the number of reads at different levels. Y-axis, number of reads; X-axis, bins of expression levels (bins at ,5
RPKM, 5–10 RPKM, 11–100 RPKM, 100–1000 RPKM and .1000 RPKM). The majority of the transcripts were expressed at low levels (,5 RPKM). RPKM,
reads per kilobase per million of reads.
doi:10.1371/journal.pone.0037159.g001
Table 4. Expression of pluripotency, differentiation and
housekeeping genes in CD90
+NTSCs and CD90
+CSCs.
Genes Mean expression (RPKM)
CD90+NTSCs CD90+CSCs
Pluripotency and differentiation
Nanog 57 61
Oct3/4 2.6 1.6
Sox18 18 15
Housekeeping
ACTB 1475 2385
GAPDH 128 179
HPRT1 3.4 2.1
PGK 28 24
No remarkable difference was observed between these two groups of CD90
+
cells. Read counts were expressed in RPKM.
doi:10.1371/journal.pone.0037159.t004
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+CSCs as compared with CD90
+NTSCs.
GeneId GeneSymbol Gene Name log2 ratio P value FDR Function
NM_130786 A1BG Alpha-1-B glycoprotein 4.645 0.026 0.032 Plasma glycoprotein
NM_001023587 ABCC5 ATP-binding cassette, sub-family C
(CFTR/MRP), member 5
1.069 0.037 0.041 Drug efflux transporter
NM_001615 ACTG2 Actin, gamma 2, smooth muscle, enteric 6.495 0.001 0.002 Cell motility
NM_001633 AMBP Alpha-1-microglobulin/bikunin precursor 1.531 0.000 0.000 Precursor of urinary trypsin inhibitor and
lipocalin transport protein
NM_001643 APOA2 Apolipoprotein A2 2.434 0.000 0.000 Stabilize high density lipoprotein (HDL)
structure and HDL metabolism
NM_000041 APOE Apolipoprotein E 2.519 0.002 0.004 Lipoprotein catabolism, binding and
internalization
NM_001645 APOC1 Apolipoprotein C1 1.601 0.000 0.000 Modulate lipoprotein interactions
NM_152547 BTNL9 Butyrophilin-like protein 9 precursor 1.693 0.000 0.000 Membrane-based protein with unknown
function
NM_001855 COL15A1 Collagen, type XV, alpha 1 2.858 0.013 0.019 Structural protein
NM_001008540 CXCR4 Chemokine (C-X-C motif) receptor 4 2.663 0.000 0.000 Receptor specific for stromal cell-derived
factor-1
NM_001135604 ESM1 Endothelial cell-specific molecule 1 2.590 0.018 0.024 Lung endothelial cell-leukocyte
interactions and endothelium-dependent
pathological disorders
NM_001442 FABP4 Fatty acid binding protein 4, adipocyte 2.183 0.000 0.000 Fatty acid uptake, transport, and
metabolism
NM_004467 FGL1 Fibrinogen-like 1 2.832 0.000 0.000 Hepatocyte mitogenic activity, HCC
development
NM_004484 GPC3 Glypican 3 2.686 0.026 0.032 Control of cell division and growth
regulation
NR_002196 H19 H19, imprinted maternally expressed
transcript (non-protein coding)
2.900 0.000 0.000 Tumor suppression
NM_000412 HRG Histidine-rich glycoprotein 1.713 0.031 0.036 Blood coagulation
NM_000599 IGFBP5 Insulin-like growth factor binding
protein 5
2.992 0.000 0.000 Prolong the half-life of the IGFs and
regulate the growth promoting effects of
IGFs
NM_002215 ITIH1 Inter-alpha (globulin) inhibitor H1 2.536 0.018 0.024 Hyaluronan synthesis, binding and
transport and stimulation of phagocytotic
cells
NM_002217 ITIH3 Inter-alpha (globulin) inhibitor H3 4.975 0.013 0.019 Extracellular matrix stabilization
NM_002291 LAMB1 Laminin, beta 1 1.633 0.037 0.041 Cell adhesion, differentiation and
migration
NM_005947 MT1B Metallothionein 1B 6.818 0.000 0.000 Bind heavy metals
NM_000607 ORM1 Orosomucoid 1 2.699 0.000 0.000 Unknown but suspected to be linked to
immunosuppression
NM_001145031 PLAU Plasminogen activator, urokinase 2.348 0.032 0.037 Degradation of the extracellular matrix
NM_006622 PLK2 Polo-like kinase 2 2.320 0.000 0.000 Regulation cell cycle progression, mitosis,
cytokinesis, and DNA damage response
NM_031310 PLVAP Plasmalemma vesicle associated protein 1.804 0.000 0.000 Formation of stomatal, microvascular
permeability and fenestral diaphragms
NM_015869 PPARG Peroxisome proliferator-activated
receptor gamma
2.501 0.010 0.015 Regulation of adipocyte differentiation
NM_012212 PTGR1 Prostaglandin reductase 1 1.629 0.023 0.029 Inactivation of the chemotactic factor,
leukotriene B4
NM_021033 RAP2A RAP2A, member of RAS
oncogene family
2.110 0.031 0.036 GTPase activity
NM_001085 SERPINA3 Serpin peptidase inhibitor, clade A
(alpha-1 antiproteinase,
antitrypsin), member 3
1.509 0.031 0.036 Plasma protease inhibitor
NM_012339 TSPAN15 Tetraspanin 15 4.210 0.000 0.000 Regulation of cell development,
activation, growth and motility
doi:10.1371/journal.pone.0037159.t005
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2CD90
+ cells in
HCC tumor tissues
Among the genes identified by RNA-Seq, GPC3 was selected for
further investigation because it is uniquely expressed in liver
CD90
+CSCs but absent in CD90
+NTSCs. Immunohistochemistry
revealedstrongGPC3expressionin34outofforty-twoHCCtumor
tissues (80.9%), but no expression was detected in non-tumorous
tissues(Figure5A).Thisresultwasinconcordancewiththeprevious
findings that GPC3 was differentially expressed in HCC [31].
Our results also showed the presence of liver CD45
2 CD90
+
cancer stem cells in all forty-two HCC tumor tissues (0.06–4.59%
in gated cells) in flow cytometry (Figure 5B), indicating a high
specificity of CD90
+CSC cells in HCC. Interestingly, a significant
positive correlation between GPC3 expression and CD45
2CD90
+
cancer stem cells was found in the HCC tumor tissues (Spearman
r=0.5997, P,0.0001; Figure 5C).
Expression of CD90
+GPC3
+ cells in HCC cell lines and
human HCC tissues
To validate the specificity and abundance of GPC3 in
CD90
+CSCs, two-color flow cytometry was used to measure the
expression of total GPC3 (both cell membrane and cytoplasm)
[31] in CD90
+CSCs derived from two HCC cell lines. GPC3 was
distinctly expressed in CD90
+ cells derived from PLC cell line
(95.3%, Figure 6A) and MHCC97L cell line (99.0%, Figure 6B).
This result indicated predominant expression of GPC3 in liver
CSCs. Further study on human HCC tissues also demonstrated
that GPC3 was highly expressed in liver CD90
+CSCs (median,
86.4%; range, 54.2–91.0%; n=5; Figure 6C).
Owing to the high expression of GPC3 in liver cancer stem cells,
additional functional studies were performed to investigate if
GPC3 has pivotal roles in regulating the growth of liver cancer
stem cells.
Table 6. List of down-regulated genes in CD90
+CSCs as compared with CD90
+NTSCs.
GeneId GeneSymbol Gene Name log2 ratio P value FDR Function
NM_006988 ADAMTS1 ADAM metallopeptidase with
thrombospondin type 1 motif, 1
23.275 0.000 0.000 Kidney development
NM_170697 ALDH1A2 Aldehyde dehydrogenase 1 family,
member A2
26.559 0.000 0.000 Liver development
NM_001039667 ANGPTL4 Angiopoietin-like 4 21.900 0.000 0.000 Hypoxia
NM_005173 ATP2A3 ATPase, Ca++ transporting, ubiquitous 23.683 0.019 0.025 Nucleotide binding
NM_133468 BMPER BMP binding endothelial regulator 24.778 0.003 0.005 Inhibitor of bone morphogenetic
protein (BMP) function
NM_002982 CCL2 Chemokine (C-C motif) ligand 2 26.608 0.000 0.000 Moncyte chemotaxis
NM_033027 CSRNP1 Cysteine-serine-rich nuclear protein 1 22.647 0.001 0.002 Transcription factor regulation
NM_001554 CYR61 Cysteine-rich, angiogenic inducer, 61 22.900 0.000 0.000 Cell adhesion
NM_001511 CXCL1 Chemokine (C-X-C motif) ligand 1
(melanoma growth stimulating
activity, alpha)
23.078 0.037 0.041 Chemotaxis
NM_001955 EDN1 Endothelin 1 23.670 0.000 0.000 Response to hypoxia
NM_001130055 EEF1D Eukaryotic translation elongation factor 1
delta (guanine nucleotide exchange
protein)
21.236 0.000 0.000 Translation elognation activity
NM_005438 FOSL1 FOS-like antigen 1 23.834 0.001 0.002 Transcription factor regulation
NM_000518 HBB Hemoglobin, beta 22.335 0.000 0.000 Oxygen transporter activity
NM_181054 HIF1A Hypoxia inducible factor 1, alpha subunit
(basic helix-loop-helix transcription factor)
21.788 0.048 0.049 Response to hypoxia
NM_033439 IL33 Interleukin 33 22.085 0.011 0.016 Cytokine acitivity
NM_000600 IL6 Interleukin 6 (interferon, beta 2) 27.169 0.000 0.000 Cytokine acitivity
NM_000584 IL8 Interleukin 8 23.981 0.037 0.041 Chemotaxis
NM_002391 MDK Midkine (neurite growth-promoting
factor 2)
21.832 0.002 0.004 Nucleotide binding Function
NM_006325 RAN RAN, member RAS oncogene family 22.153 0.000 0.000 RNA binding Function
NM_001004 RPLP2 Ribosomal protein, large, P2 21.714 0.000 0.000 RNA binding Function
NM_004704 RRP9 Ribosomal RNA processing 9, small
subunit (SSU) processome component,
homolog (yeast)
21.711 0.048 0.049 Processing of pre-ribosomal RNA
NM_003955 SOCS3 Suppressor of cytokine signaling 3 21.591 0.000 0.000 Response to hypoxia
NM_003254 TIMP1 TIMP metallopeptidase inhibitor 1 24.580 0.000 0.000 Extracellular matrix de
NM_016639 TNFRSF12A Tumor necrosis factor receptor
superfamily, member 12A
23.592 0.001 0.002 Apoptosis
NM_080682 VCAM1 Vascular cell adhesion molecule 1 23.633 0.000 0.000 Cell adhesion
NM_001025370 VEGFA Vascular endothelial growth factor A 23.399 0.037 0.040 Response to hypoxia
doi:10.1371/journal.pone.0037159.t006
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PLC CD90
+GPC3
+ CSCs were sorted using FACS with the
conjugated antibodies of FITC-GPC3 and PE-CD90 (Figure 7).We
transfected PLC CD90
+GPC3
+ cells with either GPC3-specific
siRNA or scrambled control. The efficacy of knockdown was
determined by qRT-PCR at various time points. More than 90%
inhibition of mRNA expression of GPC3 was achieved (Figure 8A).
Consistently, by flow cytometry, the percentage of GPC3
expressing cells was reduced by more than 43% after GPC3
knockdown when compared to the negative control (Figure 8B).
There was no remarkable change in the percentage of
CD90
+CSCs in PLC cells upon GPC3 transfection, implicating
that GPC3 suppression has no effect on the liver CD90
+CSCs.
Effect of GPC3 on cell proliferation and colony formation
of liver CD90
+CSCs cells
When the proliferation rate was compared between PLC
CD90
+GPC3
+(GPC32) and CD90
+GPC3
+ (SSC) over a 4-day
period, we noted no difference in cell proliferation between these
two groups of cells. This suggested that the GPC3 does not play a
role in regulating cell proliferation of the liver CD90
+CSCs
(Figure 9A).
Clonogenicity is one of the fundamental properties of cancer
stem cell, which was measured in PLC CD90
+GPC3
+(GPC32) and
PLC CD90
+GPC3
+ (SSC) cells. As shown in Figure 9B, both types
of cells had similar clonogenic capacity.
Figure 2. Correlation between qRT-PCR and RNA-Seq data.
Correlation between qRT-PCR and RNA-Seq data of 47 selected genes:
28 up-regulated genes and 19 down-regulated genes in 3 pairs of
amplified RNA samples. Spearman Rank Correlation coefficient=0.88
(P,0.001) and slope=0.73.
doi:10.1371/journal.pone.0037159.g002
Figure 3. Prospective validation of RNA-Seq analysis using an independent cohort of 12 patients by qRT-PCR. Twenty-seven up-
regulated genes and 15 down-regulated genes were selected for validation. The fold changes of selected genes measured by qRT-PCR were
statistically significant (P,0.05). Gene expression difference was considered to be valid if the direction of change was the same (as estimated by RNA-
Seq analysis). The percentage of concordance of qRT-PCR with the change of direction estimated by RNA-Seq analysis for the selected genes was
80%. *: The expression of GPC3 in CD90
+NTSCs was not detected and its fold change could not be calculated. Further analysis by Fluidigm digital
array confirmed the finding. **: The expression of BMPER in CD90
+CSCs was not detected. Further analysis by Fludigim digital array confirmed the
finding.
doi:10.1371/journal.pone.0037159.g003
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suggest that GPC3 is not involved in regulating the studied
properties of liver cancer stem cells.
Discussion
The current strategy of the new anti-cancer therapies focuses on
complete eradication of CSCs by targeting at Wnt/ß-catenin,
Figure 4. Read distribution along the GPC3 gene and quantitative measurement of mRNA GPC3 by Fluidigm digital array assay. (A)
Alignment of RNA-Seq sequence reads to GPC3 gene. Significantly higher read counts were detected for CD90
+CSCs when compared with those of
CD90
+NTSCs, indicating the specificity of GPC3 in liver CD90
+CSCs. For illustration purpose, only one exon of the gene was shown. (B) Each digital
array chip can run twelve samples. The six samples of the right hand side of the chip were CD90
+CSCs, and of the left hand side were the
corresponding CD90
+NTSCs. Digital array partitioned a RNA sample premixed with RT-PCR reagents into individual 765 RT-PCR reactions. In each
partition, the red color indicated positive expression of GPC3 at mRNA level, whereas grey indicated no expression. The GPC3 mRNA level was
quantified by counting the positive signals by the software. The mRNA expression of GPC3 was predominantly expressed in CD90
+CSCs as compared
with CD90
+NTSCs (P,0.05).
doi:10.1371/journal.pone.0037159.g004
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renewal process of CSCs. Because these developmental signaling
cascades also interact with other pathways in normal biological
functions, concerns are raised that normal stem cells will be
unavoidably damaged due to non-specificity of current anti-cancer
therapies [32]. Therefore, specific targeting of CSCs while
preserving their normal counterparts should be the appropriate
approach, but the success relies on identification of specific target
genes in CSCs. In this study, the gene expression differences
between CD90
+CSCs from tumor tissue and CD90
+NTSCs from
non-tumorous counterparts were identified by RNA-Seq, and the
up-regulated genes in CD90
+CSCs were associated with the
biological processes of liver inflammation, chemoresistance and
lipid metabolism.
Emerging evidence show that chronic inflammatory disorders
predispose to cancer development, but the underlying mechanisms
are not fully understood. HCC is a typical inflammation-related
cancer that develops slowly on a background of chronic liver
inflammation, mainly triggered by the hepatitis virus, such as
hepatitis B and C. The host immune system is activated upon
inflammation and creates inflammatory microenvironment com-
posing of leukocyte infiltrates, activated resident macrophages and
the consistent generation of cytokines within the diseased liver
[33]. In this study, a higher expression of genes in CD90
+NTSCs
that facilitated the activation of resident macrophages, recruitment
of inflammatory cells and release of cytokines for attempting to
eliminate viral-infected liver cells as a protective mechanism were
found. However, the host adaptive immune response to viral
hepatitis is not sufficient to get rid of infection completely, leading
to persistent immune-mediated liver injury, which becomes an
important procarcinogenic factor.
Additionally, these immune responses may even facilitate
growth, progression and metastasis of tumor cells [33]. Further,
the up-regulated genes in CD90
+CSCs were associated with
biological processes of wound healing, inflammation, and response
to external stimuli that might aggravate chronic liver inflamma-
tion. As a result, an inflammatory microenvironment was
established that accelerates tumor growth and progression.
Interestingly, the gene expression of IL6 and CCL2, which
regulate cell motility, was low or even absent in CD90
+CSCs, but
were highly expressed in CD90
+NTSCs, suggesting that liver
CSCs might attempt to escape immune attacks by monocyte
infiltrations. It has been shown that excessive monocyte infiltra-
tions were associated with tumor regression [34]. It appears that
the overall effects of liver inflammation favor survival and
progression of CD90
+CSCs. Hence, it is reasonable to believe
that anti-inflammatory therapies would induce adverse effects on
the activities of CD90
+CSCs. Besides, the over-expressed genes in
CD90
+CSCs were associated with responses to chemical stimulus.
One of the genes involved in this category, ABCC5, is a
membrane-bound protein drug transporter and is up-regulated
in HCC cells [35]. The over-expression of ABCC5 gene results in
elevated production of drug transporter proteins, which protect
the liver CSCs from chemotherapeutic drugs by pumping drugs
out of the cells.
In our study, genes that are associated with the lipid metabolism
were more prominent in CD90
+CSCs as compared with
CD90
+NTSCs. A recent finding has demonstrated that genes
involved in the lipid metabolism are crucial in cell transformation
and over-expressed in tumor tissues [36]. Diabetes and non-
alcoholic fatty liver disease may significantly increase the risk of
developing HCC when other risk factors, such as hepatitis B virus,
are present [37]. It is speculated that metabolic diseases, such as
diabetes mellitus, and cancer may share common disrupted
metabolic pathways [36]. In our study, APOE and APOC1 were
highly expressed in CD90
+CSCs as compared with
CD90
+NTSCs, but their functional attributes in liver CSCs
remained to be clarified. Nevertheless, APOE is known to be
involved in signal transductions that are important in tumor cell
survival, proliferation and migration [38]. Elevation of APOC1
expression was associated with tumor cell survival in pancreatic
cancer [39]. Because cholesterol is an essential component of cell
membranes, rapid growth and cell division of tumor cells depend
on cholesterol availability. In addition, cholesterol trafficking
influences the generation of essential signaling intermediates, such
as arachidonic acid, which are crucial in regulating cellular
activities. Therefore, the CD90
+CSCs with active genes in lipid
transport are believed to facilitate its proliferation, differentiation,
growth and progression.
The level of endothelial cell specific molecule-1 (ESM-1) mRNA
was highly expressed in CSCs, which was aligned with its function
in inflammatory responses and tumor progression [40]. In
addition, ESM-1 is associated with angiogenesis [41]. In this
study, concomitant up-regulated expression of ESM-1 mRNA
with PLVAP mRNA in CSCs was found. Evidence has
demonstrated that PLVAP expression is regulated by VEGF
signaling and interacts with tumor angiogenesis [42]. Taken these
together, simultaneous elevation of ESM-1 and PLVAP in CSCs
suggested that CSCs is crucial for HCC development through
promoting angiogenesis.
Among the genes identified, we found that the mRNA level of
GPC3 is nearly absent in the CD90
+NTSCs, but is highly
expressed in CD90
+CSCs. Recent studies have shown over-
expression of GPC3 in HCC [43,44]. GPC3 is highly expressed in
fetal liver, but gradually the expression is decreased towards birth
[45]. Interestingly, GPC3 expression resumes in the HCC tissue
during hepatic carcinogenesis [45]. In our present study we also
found a positive correlation between GPC3 expression and the
Table 7. Enrichment of genes involved in biological process
in CD90
+CSCs.
Gene Ontology
Number of
genes
Adjusted P
value
Up-regulated genes
Response to external stimulus 32 3.05E-10
Response to wounding 26 3.05E-10
Acute phase response 9 5.46E-10
Response to chemical stimulus 10 5.46E-10
Inflammatory response 19 1.69E-08
Phospholipid efflux 6 2.95E-09
Cholesterol transport 6 7.88E-08
Regulation of small RNA production 18 7.88E-08
Homeostatsis 12 7.88E-08
Down-regulated genes
Translational elongation 30 1.07E-20
Cell motion 44 2.32E-09
Cell localization 44 2.32E-09
Anti-apoptosis 26 3.84E-09
Negative regulation of cellular process 75 8.12E-09
Angiogenesis 22 8.94E-09
Only categories with three or more candidate genes are shown.
doi:10.1371/journal.pone.0037159.t007
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+CSCs present in the liver tumor tissues,
suggesting that GPC3 expression could indicate the amount of
liver cancer stem cells in tumors. Owing to the small number of
cases and short follow-up period, correlation analysis of survival or
other clinico-pathological features with the number of
CD90
+CSCs or GPC3 could not be accurately evaluated.
Nevertheless, a previous study using the same protocol of GPC3
immunohistochemical staining has shown that GPC3-positive
HCC patients (.10% of GPC-positive cells in immunohistochem-
ical staining) have a lower 5-year survival rate than GPC-negative
HCC patients (,10% of GPC-positive cells in immunohistochem-
ical staining [46]. Taken our results together with their findings,
GPC3 expression in liver tumor tissues may reflect the abundance
of liver cancer stem cells, which may have a prognostic value for
HCC patients. Additionally, it was shown that GPC3 was highly
expressed in CD90
+CSCs in liver cancer cell lines and human
tumor tissues, implicating that GPC3 is a specific marker for liver
CD90
+CSCs. Some studies demonstrated that GPC3 plays an
important role in the cell growth and differentiation by interacting
with heparin-binding growth factors, such as IGF and Wnts
[47,48]. Besides, GPC3 has been shown to induce ERK1/2 and
AKT phosphorylation that eventually contributes to anti-apopto-
sis, invasion, and survival of tumor cells [49]. On the other hand,
some other studies reported that endogenous GPC3 inhibited the
cell proliferation of liver cancer cells [50,51]. Another recent study
demonstrated that GPC3 acts as a negative regulator of cell
proliferation, but this mechanism may be defective in HCC and
thereby cancer cells are unresponsive to over-expressed GPC3
signal [52]. All these studies suggested that the role of GPC3 in
HCC is elusive. In this study, we showed that GPC3 did not have
Figure 5. GPC3 expression and quantification of CD90
+ cells in human liver tumor tissues. (A) Immunohistochemistry detected strong
signals of GPC3 in liver tumor tissue, but negative staining for GPC3 was detected in the adjacent non-tumorous tissue (magnification6200). (B) Flow
cytometry detected more CD45
2CD90
+ cells in tumor tissues (median, 0.645%; range, 0.06–4.59% of the gated cells) than that in adjacent non-
tumorous tissues (median, 0.175%; range, 0.00–1.14%). (C) The number of CD45
2CD90
+cells was positively correlated with GPC3 expression level in
the tumor tissues (Spearman correlation coefficient=0.5997, P,0.0001).
doi:10.1371/journal.pone.0037159.g005
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+GPC3
+ cells in CD90
+CSCs derived from human HCC cell lines and liver tumors. A significant
increase in the number of CD90
+GPC3
+ cells were detected within CD90
+ cell population of PLC and MHCC97L cells. (A) In PLC cells, 95.3% of CD90
+
cells co-expressed GPC3. (B) In MHCC97L cells, 99.0% of CD90
+ cells co-expressed GPC3. (C) Analysis of a representative pair of human liver tissues
indicated that only 4.5% of CD90
+ population expressed GPC3 in non-tumorous tissues, while 89.9% of CD90
+ cells expressed GPC3 in the matched
tumorous tissues (median, 86.4%; range, 54.2–91.0%; n=5). These results demonstrated that GPC3 is distinctly expressed in liver CD90
+CSCs.
doi:10.1371/journal.pone.0037159.g006
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exact role of GPC3 on cancer stem cells therefore needs further
investigation.
Regardless of its ambiguous functional roles on HCC, GPC3 is
a potential target gene for liver cancer therapy because it is highly
expressed in HCC but is absent in normal liver tissues. Making use
of this distinct feature of GPC3 in HCC, an anti-GPC3 antibody
therapy or antibody-drug conjugate (ADC) could be used as a
biological missile targeting the GPC3-expressing cells, including
liver cancer cells [53] and CD90
+CSCs. The binding of the target
cells by ADC target therapy would release the linked cytotoxic
drug once the conjugate is internalized into the cells and
eventually eradicate both cancer cells and CSCs. In a recent
study, the GPC3-antibody approach aroused antibody-dependent
cellular cytotoxicity, which caused liver tumor growth retardation
in an animal model [54]. The phase I clinical trial using GPC3 for
liver cancer is ongoing [55]. Elimination of liver cancer stem cells
could be potentially achieved by this molecular targeted therapy.
In summary, the present study has identified a set of genes
differentially expressed by liver CSCs that are enriched in several
biological processes including inflammation, drug resistance and
Figure 7. Double immunofluorescence staining of CD90 and
GPC3 in sorted PLC CD90
+GPC3
+ cells. The sorted cells were
stained with fluorescein-conjugated anti-CD90 and anti-GPC3 antibod-
ies. Nuclei were counterstained by DAPI. The merge image showed the
expression of CD90 and GPC3 in both cytoplasm and cell membrane.
doi:10.1371/journal.pone.0037159.g007
Figure 8. Effective knockdown of GPC3 in PLC CD90
+GPC3
+ cells. The sorted PLC CD90
+GPC3
+ cells were transfected with either 20 nM
specific GPC3 siRNA or a scrambled siRNA control and incubated for 24 hours. (A) GPC3 knockdown in the target cells reduced the gene expression
by 90% as measured by qRT-PCR. (B) By flow cytometry, the number of GPC3-expressing cells was decreased by 43% upon GPC3 knockdown when
compared to the scrambled control (decreased from 3.9% to 2.2%).
doi:10.1371/journal.pone.0037159.g008
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distinctly expressed in liver CD90
+CSCs but not in
CD90
+NTSCs, such as GPC3, could be promising candidates
for immunotherapy, which could eliminate liver cancer stem cells
and adult cancer cells without inducing damage to normal liver
cells. The present study provides clues for the development of new
drugs targeting against liver CSCs and may lead to an
improvement in the outcomes of HCC patients.
Supporting Information
Figure S1 CD90
+ cells sorting. CD90
+ cells were sorted from
tumor and adjacent non-tumorous human liver tissues using a BD
FACSAria II Cell Sorter. The purity of CD90
+ was about 86.6%.
(TIF)
Table S1 Primers used in qRT-PCR for the validations
of RNA-sequencing data.
(DOC)
Acknowledgments
We thank Xueda Hu, Li Chen, and Xuemei Tan for conducting the RNA-
Sequencing experiments, and Dr. Chi Keung Lau for designing the
primers.
Author Contributions
Conceived and designed the experiments: ZFY STF. Performed the
experiments: DWYH CTL MNPN JL TW. Analyzed the data: KY XQW
ZY HL YZ. Contributed reagents/materials/analysis tools: WCY. Wrote
the paper: DWYH.
Figure 9. Effect of GPC3 on cell proliferation and clonogenic capacity of liver CD90
+GPC3
+CSCs. (A) Cell proliferation was assessed after
GPC3 knockdown in PLC CD90
+GPC3
+ cancer stem cells. No significant effect of GPC3 on liver cancer stem cell proliferation was found. (B)
Knockdown of GPC3 in PLC CD90
+GPC3
+ cancer stem cells by siRNA did not affect their colony formation ability, indicating that GPC3 had no impact
on clonogenicity of the liver cancer stem cells.
doi:10.1371/journal.pone.0037159.g009
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